Journal
CANCERS
Volume 13, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/cancers13174455
Keywords
breast cancer; biomarker; Ki-67; MIB-1; personalised medicine
Categories
Funding
- National Breast Cancer Research Institute, Ireland
Ask authors/readers for more resources
In breast cancer development, the expression of Ki-67 is a valuable indicator for prognosis and treatment decision making. The advent of molecular medicine has transformed breast cancer management by recognizing the heterogeneity of the disease and using a combination of factors for substratification and personalization of treatment modalities. Routine evaluation of Ki-67 as a proliferation marker in breast cancer patients has limitations, but promising strategies are being explored to enhance its utility in future oncology.
Simple Summary In breast cancer development, the expression of Ki-67 is strongly associated with cancer proliferation and is a known indicator of prognosis and outcome. Ki-67 expression levels are also useful to inform treatment decision making in some cases. As a result, routine measurement of Ki-67 is now widely performed during pathological tumour evaluation. However, the Ki-67 appraisal is not without its limitations and shortcomings-the aim of this study was to provide an overview of Ki-67 use in the clinical setting, the current challenges associated with its measurement, and the novel strategies that will hopefully enhance Ki-67 proliferation indices for prospective breast cancer patients. The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available